Safety and immunobiological activity of guadecitabine sequenced with ipilimumab in metastatic melanoma patients: The phase Ib NIBIT-M4 study.

被引：1
|
作者：
Di Giacomo, Anna Maria
Covre, Alessia
Finotello, Francesca
Rieder, Dietmar
Sigalotti, Luca
Giannarelli, Diana
Petitprez, Florent
Lacroix, Laetitia
Cutaia, Ornella
Fazio, Carolina
Coral, Sandra
Anichini, Andrea
Bock, Christoph
Lowder, James N.
Azab, Mohammad
Fridman, Wolf-Herman
Sautes-Fridman, Catherine
Trajanoski, Zlatko
Maio, Michele
机构：
[1] Univ Hosp Siena, Med Oncol & Immunotherapy, Siena, Italy
[2] Univ Hosp Siena, Ctr Immunooncol, Siena, Italy
[3] Med Univ Innsbruck, Bioctr, Div Bioinformat, Innsbruck, Austria
[4] Ctr Riferimento Oncol CRO Aviano, Oncogenet & Funct Oncogen Unit, Aviano, Italy
[5] Regina Elena Inst Canc Res, IRCSS, Rome, Italy
[6] Cordeliers Res Ctr, INSERM, UMR S 1138, Paris, France
[7] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[8] Austrian Acad Sci, CeMM Res Ctr Mol Med, Vienna, Austria
[9] Astex Pharmaceut, Dublin, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.2549
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2549
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma
    Amin, Asim
    Lawson, David H.
    Salama, April K. S.
    Koon, Henry B.
    Guthrie, Troy, Jr.
    Thomas, Sajeve S.
    O'Day, Steven J.
    Shaheen, Montaser F.
    Zhang, Bin
    Francis, Stephen
    Hodi, F. Stephen
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2016, 4
  • [42] Evaluation of photosensitivity in dabrafenib treated metastatic melanoma patients: Results from a phase Ila study.
    Eigentler, Thomas K.
    Ghoreschi, Kamran
    Berneburg, Mark
    Garbe, Claus
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [43] Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204.
    Tawbi, Hussein Abdul-Hassan
    Forsyth, Peter A. J.
    Algazi, Alain Patrick
    Hamid, Omid
    Hodi, F. Stephen
    Moschos, Stergios J.
    Khushalani, Nikhil I.
    Gonzalez, Rene
    Lao, Christopher D.
    Postow, Michael Andrew
    Atkins, Michael B.
    Ernstoff, Marc S.
    Puzanov, Igor
    Kudchadkar, Ragini Reiney
    Thomas, Reena Parada
    Tarhini, Ahmad A.
    Jiang, Joel
    Avila, Alexandre
    Demelo, Sheena
    Margolin, Kim Allyson
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [44] Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma.
    Atkins, Michael B.
    Reiney, Ragini
    Sznol, Kudchadkar Mario
    McDermott, David F.
    Lotem, Michal
    Schachter, Jacob
    Wolchok, Jedd D.
    Urba, Walter John
    Kuzel, Timothy
    Schuchter, Lynn Mara
    Slingluff, Craig L.
    Ernstoff, Marc S.
    Fay, Joseph W.
    Friedlander, Philip Adam
    Gajewski, Thomas
    Zarour, Hassane M.
    Rotem-Yehudar, Rinat
    Sosman, Jeffrey Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [45] Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study
    Di Giacomo, A. M.
    Ascierto, P. A.
    Queirolo, P.
    Pilla, L.
    Ridolfi, R.
    Santinami, M.
    Testori, A.
    Simeone, E.
    Guidoboni, M.
    Maurichi, A.
    Orgiano, L.
    Spadola, G.
    Del Vecchio, M.
    Danielli, R.
    Calabro, L.
    Annesi, D.
    Giannarelli, D.
    Maccalli, C.
    Fonsatti, E.
    Parmiani, G.
    Maio, M.
    ANNALS OF ONCOLOGY, 2015, 26 (04) : 798 - 803
  • [46] Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial
    Weber, Jeffrey S.
    Amin, Asim
    Minor, David
    Siegel, Jonathan
    Berman, David
    O'Day, Steven J.
    MELANOMA RESEARCH, 2011, 21 (06) : 530 - 534
  • [47] A phase IB study of ipilimumab with peginterferon alfa-2b for patients with unresectable stages IIIB/C/IV melanoma.
    Kudchadkar, Ragini Reiney
    Gibney, Geoffrey Thomas
    Dorman, Denise
    Merek, Stephanie
    Ramadan, Howida
    Chen, Ann
    Weber, Jeffrey S.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [48] Phase 1 study of NY-ESO-1 vaccine + ipilimumab (IPI) in patients with unresectable or metastatic melanoma.
    Slingluff, Craig L.
    Zarour, Hassane M.
    Postow, Michael A.
    Friedlander, Philip Adam
    Devoe, Craig E.
    Smith, Kelly
    Deacon, Donna
    Macri, Mary J.
    Ryan, Aileen
    Venhaus, Ralph Rudolph
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [49] Phase 1 study to evaluate safety and efficacy of nivolumab (nivo) plus ipilimumab (ipi) plus external beam radiotherapy (RT) in patients with metastatic melanoma.
    Postow, Michael A.
    Knox, Susan Jane
    Goldman, Debra
    Panageas, Katherine
    Halpenny, Darragh
    McCabe, Danielle
    Macri, Mary J.
    Schwarzenberger, Paul
    Ricciardi, Toni
    Ryan, Aileen
    Venhaus, Ralph Rudolph
    Barker, Christopher Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [50] Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial
    Di Giacomo, A. M.
    Sileni, V. Chiarion
    Del Vecchio, M.
    Ferrucci, P. F.
    Guida, M.
    Quaglino, P.
    Guidoboni, M.
    Marchetti, P.
    Simonetti, E.
    Amato, G.
    Covre, A.
    Camerini, R.
    Calabro, L.
    Valente, M.
    Mandala, M.
    Giannarelli, D.
    Maio, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S653 - S654
12345